

## Bioinformatics Analysis of Gestational Diabetes Mellitus using Functional Protein Sequences

ALLAM APPARAO<sup>1</sup>, SURESH KOPPARTHI<sup>2</sup>, UDURTI N DAS<sup>3</sup>, SRIDHAR GUMPENY<sup>4</sup>

<sup>1</sup>Dept of CSE, Andhra University, Visakhapatnam, AP, India, E-mail: allamapparao@gmail.com

<sup>2</sup>Research Scholar, Department of Computer sciences and Engineering, Acharya Nagarjuna University, Guntur, AP, India, E-mail: sureshkgrl@gmail.com

<sup>3</sup>UND Life Sciences, 13800 Fairhill Road, Shaker Heights, OH 44120, USA, E-mail: undurti@hotmail.com.

<sup>4</sup>Endocrine and Diabetes Center, Krishnanagar, Visakhapatnam, AP, India.

**Abstract:** Gestational diabetes mellitus [GDM] is a transient asymptomatic disorder in which glucose intolerance of variable severity with onset or first recognition during pregnancy. GDM is emerging as reliable risk predictor for the development of type II diabetes. GDM has also been associated with many adverse perinatal pediatric complications. It is crucial to pinpoint the key susceptible gene that is of great importance in the pathophysiology of gestational diabetes. In this regard, We evaluated the role of several genes/proteins that are believed to be involved in the evolution of Gestational diabetes by employing multiple sequence alignment using ClustalW tool and constructed a phylogram tree using functional protein sequences extracted from NCBI. Phylogram was constructed using Neighbor-Joining Algorithm in bioinformatics approach. Our bioinformatics analysis yielded Glucokinase[MODY 2] gene as a key susceptible gene closely associated with Gestational diabetes mellitus. This is the first bioinformatics study to lend further support for the proximate association between Glucokinase[MODY 2] gene and Gestational diabetes mellitus. The identification of Glucokinase mutation in a patient with gestational diabetes is important for both the mother and the baby. It is suggested that early identification of Glucokinase[MODY2] gene mutations may help to prevent the evolution of gestational diabetes and subsequently type II diabetes that develops later in the life.

**Keywords:** Gestational Diabetes Mellitus (GDM), NCBI National Center for Biotechnology Information.

### I. INTRODUCTION

Gestational diabetes mellitus [GDM] is a transient asymptomatic disorder in which glucose intolerance of variable severity with onset or first recognition during pregnancy. [1] GDM is a heterogeneous disorder associated with a high degree of maternal and fetal mortality. There is growing likelihood for the development of type 2 diabetes among women with previous history of GDM. [2]. GDM patients are also at increased risk for perinatal morbidity and long term obesity and glucose intolerance in offspring. [3]. The prevalence of GDM increased in developed countries

from 2.9% to 8.8% over the past two decades. [4]. Previous experimental studies reported that the altered metabolic environment of the gestational diabetic women produces permanent aberrations in glucose homeostasis in the offspring that evolves to diabetes later in life. [5]. GDM has been associated with many adverse perinatal pediatric outcomes. Macrosomia is the most common problem [6] and is referred as the infant birth weight over 4000 grams or over the 90<sup>th</sup> percentile of birth weight for gestational age. These large babies are at increased risk of shoulder dystocia. Neonates of gestational diabetic mothers also have an increased risk of having hypoglycemia, respiratory distress and neonatal death [7]. The offspring also tend to have increased rates of Diabetes mellitus before the age of 18. [8] Moreover, diabetic pregnancy in rat models causes multiple perturbations in glucose homeostasis and insulin secretion in the fetus that leads to defective fetal growth. The high dosage of STZ produces growth retardation in rats while the lower dosage of STZ causes fetal macrosomia in rats [5].

The pathophysiology of GDM is believed to involve a combination of increased insulin resistance and beta cell dysfunction. [9] The majority of gestational diabetic women seem to have beta cell dysfunction that occurs on a background of chronic insulin resistance. Pregnant women with GDM tend to have higher insulin resistance than normal pregnant women. [3] In normal pregnant women, insulin resistance resulted from increased maternal adiposity and insulin desensitizing effects of hormones released by placenta. Insulin resistance abates immediately after delivery suggests that insulin resistance developed during pregnancy may be majorly attributed to the placental hormones in normal pregnant women. [3] But in the case of diabetic pregnant patients, though glucose regulation usually reverts to normal following delivery, features of metabolic syndrome may persist and glucose tolerance often deteriorates with time. [10] Majority of epidemiological and experimental studies revealed that intrauterine diabetic milieu promotes the risk for hypertension, obesity and type 2 diabetes in adulthood. [11] Our Bioinformatics analysis aimed to pinpoint the key

gene/protein that has proximate association with pathobiology of GDM.

## II. MATERIAL METHODS

We collected 17 known Proteins that are believed to involve in the pathogenesis of Gestational diabetes mellitus. The functional Protein sequences in FASTA format for these Proteins are collected from NCBI [National Center for Biotechnology Information [Ref: http://www.ncbi.nlm.nih.gov]]. These sequences are given to ClustalW [Ref: http://www.ebi.ac.uk/clustalw] for the Multiple Sequence Alignment. [It calculates the best match for the selected sequences, and lines them up so that the identities, similarities and differences can be seen]. Based on these results, the scores table and Phylogenetic tree shows the distance between the Protein sequences. It is suggested that early identification of Glucokinase [MODY2] gene mutations may help to prevent the evolution of gestational diabetes and subsequently type II diabetes that develops later in the life.

## III. DISCUSSION

GDM is characterized by impaired insulin secretion and action. [12] Women with GDM often have a history of maternal diabetes that suggests a genetic component for the disease. To date, several genetic studies have been carried out to identify susceptibility genes predisposing for the development of GDM. Associations have been reported between GDM and variants in the glucokinase [13], mitochondrial DNA [14,15], beta 3 adrenergic receptor [16], sulphonyl urea receptor 1 [SUR 1] [17], Insulin receptor and Insulin like growth factor 2 [IGF2] genes [18]. Increased frequencies of HLA risk antigens and high prevalence of islet cell antibodies, insulin associated antigen 2 and GAD antibodies have also been reported in women with GDM. In addition, few studies reported the increased levels of leptin [19] and inflammatory markers of TNF-alpha [20] and C-reactive protein [21] and decreased levels of adiponectin [22,23] in women with GDM. Mutations that cause several subtypes of MODY have been found in women with GDM. These include mutations in genes encoding Glucokinase [MODY 2] [24,25-27], Hepatocyte nuclear factor-alpha [MODY 3] [24]. Glucokinase mutations cause maturity onset diabetes of young type II [MODY 2]. In MODY 2 women, hyperglycemia persists through out pregnancy. [28] Altered fetal insulin secretion caused by fetal or maternal Glucokinase mutations affect birth weight. [28] Yet, genetic and environmental components are implicated in the pathophysiology of GDM.

In consonance with the several previous experimental reports, Our bioinformatics analysis revealed that genetic component, particularly Glucokinase gene, plays predominant role in history of evolution of Gestational diabetes. Glucokinase mutations were identified in 80% of the gestational diabetic patients selected on the basis of clinical phenotype. [29] In the large group of French MODY2 families, birth weight is declined in the presence of a fetal glucokinase mutation and increased by the presence of maternal glucokinase mutation. [28] It is imperative to

identify these patients with Glucokinase mutations because they have a predictable clinical course and the autosomal dominant inheritance. [29] The identification of Glucokinase mutation in a patient with gestational diabetes is important for both the mother and the baby. [29] Patients with glucokinase mutations are frequently diagnosed during screening in pregnancy. In the series of European Whites, the prevalence of glucokinase mutations ranged from 0% to 6%. [29] The recognition of the subjects with glucokinase mutations is important because they have a different clinical course both within and outside pregnancy compared with most other subjects with gestational diabetes. Patients clinical characteristics can be used to detect those who are most likely to have a glucokinase mutation. Specific criteria favoring a diagnosis of a glucokinase mutation have been shown to be persistent fasting hyperglycemia [29].


**TABLE I: Table Showing the Genes/Proteins That Have Been Studied In the Present Study, Which Are Believed To Be Involved In Gestational Diabetes Mellitus**

S.no	Gene name	Accession number	Length	Tissue	References
1	ADIPOQ	AAH54496	244 aa	Peripheral Nervous System, sympathetic Trunk	
2	<a href="#">ADRB3</a>	NP_000016	408 aa	NOT SPECIFIED	
3	<a href="#">CRP</a>	AAH20766	91 aa	Liver	
4	<a href="#">GCK</a>	AAA67542	14 aa	Blood	
5	<a href="#">GIP</a>	AAH69746	153 aa	PCR rescued clones	
6	<a href="#">HFE</a>	AAH74721	345 aa	Brain, PCR rescued clones	
7	<a href="#">HLA-DQA1</a>	AAI25046	254 aa	PCR rescued clones	
8	<a href="#">HNF4A</a>	CAC01303	474 aa		
9	<a href="#">HP</a>	AAH70299	281 aa	Liver	
10	<a href="#">LEP</a>	AAH69452	167 aa	PCR rescued clones	
11	<a href="#">PPARBP</a>	AAH60758	556 aa	Testis	
12	<a href="#">PPARGCIA</a>	NP_037393	798 aa	No	
13	<a href="#">PTPRN</a>	AAH70053	950 aa	Brain, hypothalamus	
14	<a href="#">TNF</a>	CAI18649	233 aa		
15	SHBG	AAH69597	401 aa	PCR rescued clones	
16	IGF2	AAH42127	113 aa	Muscle, rhabdomyosarcoma	
17	SUR5	AAM44124	665 aa		

Fetal growth in pregnant patients with MODY 2 has been shown to be dependent on whether the fetus has inherited the mutation from its mother. [30] Fetal insulin secretion is a key determinant of fetal growth, acting mainly during the third trimester when the weight of the fetus increased markedly. Macrosomic children born to mothers with diabetes in pregnancy have increased fetal insulin secretion in response to fetal pancreatic sensing of maternal hyperglycemia. Factors that alter fetal insulin secretion will therefore alter intrauterine growth by altering fetal insulin mediated growth. [31] A glucokinase mutation in a pregnant mother will result in maternal hyperglycemia, hence increasing fetal insulin secretion and fetal growth as shown in Fig.1. Inheritance of the mutation by the fetus will result in reduced sensing of the maternal glucose by the fetal pancreas and hence reduced fetal

## Bioinformatics Analysis of Gestational Diabetes Mellitus using Functional Protein Sequences

insulin secretion and reduced intrauterine growth. [31] GDM provides an excellent model for studying early events in the natural history of type II diabetes and early identification of Glucokinase[*MODY2*] gene mutations may help to prevent the evolution of gestational diabetes and subsequently type 2 diabetes that develops in later in the life.



**Fig.1. The phylogenetic tree that was constructed based on the alignment score of all the protein sequences involved in Gestational diabetes mellitus.**

### IV. CONCLUSION

Gestational diabetes is great opportunity for studying early events in the development of type II diabetes. Our bioinformatics study support the dominant role of Glucokinase[*MODY 2*] gene in the evolution of gestational diabetes. The early identification of Glucokinase[*MODY 2*] gene mutations could produce promising results in the clinical practice.

### V. REFERENCES

[1] Nancy F Butte. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus *Am J Clin Nutr* 2000; 71[suppl]: 1256S–61S.  
 [2] O’Sullivan, J.B., and Mahan, C.M. 1964. Criteria for the oral glucose tolerance test in pregnancy. *Diabetes*. 13: 278–285.  
 [3] Thomas A. Buchanan and Anny H. Xiang, Gestational diabetes mellitus, the *Journal of Clinical Investigation* 2005; 115[3]: 485-491.  
 [4] Betscher, N. A., Wein, P., Sheedy, M. T. & Steffer, B. [1996] Identification and treatment of women with hyperglycemia diagnosed during pregnancy. Can significantly reduce perinatal mortality rates? *Aust. N. Z. J. Obstet. Gynaecol.* 36: 239–247.  
 [6] Judd Boloker, Shira J. Gertz, and Rebecca A. Simmons Gestational Diabetes Leads to the Development of Diabetes in Adulthood in the Rat *Diabetes* 51:1499–1506, 2002.  
 [7] Jones CW. Gestational diabetes and its impact on the neonate. *Neonatal Netw* 2001; 20[6]: 17-23. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS.

Effect of treatment of gestational diabetes on pregnancy outcomes. *N Engl J Med* 2005; 352:2477-86.  
 [8] Grigorakis SI, Alevizaki M, Beis C, Anastasiou E, Alevizaki CC, Souvatzoglou A. Hormonal parameters in gestational diabetes mellitus during the third trimester : Glucagon levels. *Gynecol Obstet Invest* 2000; 49[2]: 106-9.  
 [9] M. Tomazic<sup>1</sup>, A. Janez<sup>1</sup>, A. Sketelj<sup>2</sup>, A. Kocijancic<sup>1</sup>, J. Eckel<sup>3</sup>, P.M. Sharma<sup>4</sup> Comparison of alterations in insulin signalling pathway in adipocytes from Type II diabetic pregnant women and women with gestational diabetes mellitus. *Diabetologia* [2002] 45:502–508.  
 [11] E. Kousta . Z. Efstathiadou . N. J. Lawrence . J. A. R. Jeffs. I. F. Godsland . S. C. Barrett . C. J. Doré . A. Penny . V. Anyaoku. B. A. Millauer . E. Cela. S. Robinson . M. I. McCarthy. D. G. Johnson . The impact of ethnicity on glucose regulation and the metabolic syndrome following gestational diabetes. *Diabetologia* [2006] 49: 36–40 Hiroshi Yamashita, Jianhua Shao, Tatsuya Ishizuka, Patrick J. Klepcyk, Peggy Muhlenkamp, Liping Qiao, Nigel Hoggard, and Jacob E. Friedman . Leptin Administration Prevents Spontaneous Gestational Diabetes in Heterozygous *Lepr<sup>db/1</sup>* Mice: Effects on Placental Leptin and Fetal Growth. *Endocrinology* **142**: 2888–2897, 2001.  
 [12] N. Shaat<sup>1</sup>, M. Ekelund, Å. Lernmark<sup>1</sup>, S. Ivarsson, A. Nilsson, R. Perfekt, K. Berntorp<sup>1</sup>, L. Groop. Genotypic and phenotypic differences between Arabian and Scandinavian women with gestational diabetes mellitus. *Diabetologia* [2004] 47:878–884.  
 [13] Ellard S, Beards F, Allen LI et al. [2000] A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. *Diabetologia* 43:250–253.  
 [14] Chen Y, Liao WX, Roy AC, Loganath A, Ng SC [2000]. Mitochondrial gene mutations in gestational diabetes mellitus. *Diabetes Res Clin Pract* 48:29–35  
 [15] Yanagisawa K, Uchigata Y, Sanaka M et al. [1995]. Mutation in the mitochondrial tRNA[*leu*] at position 3243 and spontaneous abortions in Japanese women attending a clinic for diabetic pregnancies. *Diabetologia* 38:809–815  
 [16] Festa A, Krugluger W, Shnawa N, Hopmeier P, Haffner SM, Schernthaner G [1999] Trp64Arg polymorphism of the beta3-adrenergic receptor gene in pregnancy association with mild gestational diabetes mellitus. *J Clin Endocrinol Metab* 84:1695–1699.  
 [17] Rissanen J, Markkanen A, Karkkainen P et al. [2000]. Sulfonylurea receptor 1 gene variants are associated with gestational diabetes and type 2 diabetes but not with altered secretion of insulin. *Diabetes Care* 23:70–73.  
 [18] Ober C, Xiang KS, Thisted RA, Indovina KA, Wason CJ, Dooley S [1989] Increased risk for gestational diabetes mellitus associated with insulin receptor and insulin-like growth factor II restriction fragment length polymorphisms. *Genet Epidemiol* 6:559–569.  
 [19] Kautzky-Willer A, Pacini G, Tura A, Biegelmayer C, Schneider B, Ludvik B, Prager R, Waldhäusl W. 2001. Increased plasma leptin in gestational diabetes. *Diabetologia* 44:164–172.

- [20] Winkler G, Cseh K, Baranyi E, Melczer Z, Speer G, Hajós P, Salamon F, Turi Z, Kovács M, Vargha P, Karádi I. 2002. Tumor necrosis factor system and insulin resistance in gestational diabetes. *Diabetes Res. Clin. Pract.* 56:93–99.
- [21] Ravi Retnakaran, Anthony J. G. Hanley, NurytRaif, Philip W. Connelly, Mathew Sermer and Bernard Zinman 2003. C-reactive protein and gestational diabetes: the central role of maternal obesity. *J. Clin. Endocrinol. Metab.* 88:3507–3512.
- [22] Ravi Retnakaran, Anthony J.G. Hanley, NurytRaif, Philip W. Connelly, Mathew Sermer and Bernard Zinman. 2004. Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. *Diabetes Care.* 27:799–800.
- [23] Michelle A. Williams, Chunfang Qiu, Martin Muiy-Rivera, Surab Vadachkoria, Tara Song and David A. Luthy. 2004. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. *J. Clin. Endocrinol. Metab.* 89:2306–2311.
- [24] Weng J, Ekelund M, Lehto M, Li H, Ekberg G, Frid A, Aberg A, Groop LC, Berntorp K. 2002. Screening for MODY mutations, GAD antibodies, and type 1 diabetes-associated HLA genotypes in women with gestational diabetes mellitus. *Diabetes Care.* 25:68–71.
- [25] Kousta E, Ellard S, Allen LI, Saker PJ, Huxtable SJ, Hattersley AT, McCarthy MI. 2001. Glucokinase mutations in a phenotypically selected multiethnic group of women with a history of gestational diabetes. *Diabet. Med.* 18:683–684.
- [26] Ellard S, Beards F, Allen LI, Shepherd M, Ballantyne E, Harvey R, Hattersley AT 2000. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. *Diabetologia.* 43: 250–253.
- [27] Saker PJ, Hattersley AT, Barrow B, Hammersley MS, McLellan JA, Lo YM, Olds RJ, Gillmer MD, Holman RR, Turner RC. 1996. High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population. *Diabetologia.* 39:1325–1328.
- [28] Velho G, Hattersley AT, Froguel P. Maternal diabetes alters birth weight in glucokinase deficient [Kindred but has no influence on adult weight and height, insulin secretion or insulin sensitivity. *Diabetologia*[2000]; 43: 1060-1063.
- [29] S. Ellard, F. Beards, L. I.S. Allen, M. Shepherd, E. Ballantyne, R. Harvey, A.T. Hattersley. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. *Diabetologia*[2000] 43: 250-253.
- [30] Hattersley AT, Beards F, Ballantyne E et.al. Mutations in the glucokinase gene of the fetus result in reduced birth weight. *Nat Genet* 1998;19:268-270.